3 citations
,
November 2024 in “Pediatric Dermatology” Selumetinib causes fewer and less severe skin issues in children than binimetinib.
5 citations
,
February 2024 in “Clinical Pharmacokinetics” A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
3 citations
,
August 2023 in “Drug safety” Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
10 citations
,
August 2016 in “Dermatology Online Journal” Nilotinib can cause skin issues like red bumps and hair loss.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
May 2026 in “Journal of Skin and Sexually Transmitted Diseases” Upadacitinib, a JAK1 inhibitor, has shown efficacy in treating various dermatological conditions, including atopic dermatitis and psoriasis, since its FDA approval for these uses. A comprehensive review of literature from 2015 to 2025 highlights its effectiveness, increasing real-world application, and cost-effectiveness compared to other treatments. The review includes systematic reviews, randomized controlled trials, and real-world studies, focusing on its use in cutaneous disorders while excluding non-dermatological indications and non-English articles. Upadacitinib's recent generic availability in India further supports its expanding role in dermatologic therapy.
44 citations
,
April 2006 in “Expert opinion on drug safety” Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.
4 citations
,
September 2024 in “BMC Cancer” Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 is generally safe for treating alopecia areata.
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
65 citations
,
February 2011 in “Molecular cancer therapeutics” CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.
192 citations
,
January 2015 in “Journal of the American Academy of Dermatology” Targeted cancer therapies often cause serious skin problems that need careful management.
10 citations
,
August 2012 in “Current Problems in Pediatric and Adolescent Health Care” Hair changes can indicate systemic diseases or medication effects.
December 2025 in “npj Breast Cancer” Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.
10 citations
,
September 2016 in “Journal of cutaneous medicine and surgery” Patients on dabrafenib and trametinib for melanoma often experience skin side effects.
July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
1 citations
,
April 2023 in “Heliyon” Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
4 citations
,
February 2018 in “World journal of surgical oncology” A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.
March 2026 in “British Journal of Dermatology” Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
4 citations
,
October 2019 in “Skin Appendage Disorders” Gefitinib can cause hair and eyebrow darkening.
New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.
7 citations
,
January 2022 in “SAGE open medical case reports” Upadacitinib successfully treated a child's severe skin and hair loss issues.
87 citations
,
March 2013 in “Expert Review of Anticancer Therapy” Afatinib often causes skin problems that need proactive management.
December 2025 in “Biomedicines” Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.